





MaxCyte SPL Portfolio


May 12, 2026



 MaxCyte® eexpert® AT₂ ST₂ GT₂ VL₂ DT₂ are trademarks of MaxCyte, Inc. in the U.S.A.

MaxCyte has an Active Portfolio of SPLs

-  cGMP Compatible Platform
-  FDA Master File and Technical Files
-  Experienced FAS and sales support
-  Leading know-how and engineering process improvement



12 Active Clinical Programs Represents ~\$110M of precommercial milestone potential >\$30M of milestone payments to date through SPL model

Updated as of May 2026

1. *Catamaran Bio and Walking Fish Therapeutics have ceased operations, resulting in 29 SPLs*
2. *Cleared INDs or Equivalent*
3. *Editas Medicine, Myeloid, and Vor Biopharma have announced their exit of the ex-vivo space*

SPL Portfolio: 14 Active Clinical Trials

Partner	Program	Phase	Cell Approach	Cell Type	Disease Area
Vertex Pharmaceuticals	CASGEVY	Commercial	Autologous	HSCs	Beta-thalassemia
Vertex Pharmaceuticals	CASGEVY	Commercial	Autologous	HSCs	Sickle cell disease
Wugen	WU-CART-007	Pivotal	Allogeneic	T-Cells	T Cell Lymphoma
Undisclosed Partner A	-	Pivotal	Undisclosed	Undisclosed	Undisclosed
CRISPR Therapeutics	CTX112	1/2	Allogeneic	T-Cells	Hematological Malignancies
CRISPR Therapeutics	CTX112	1/2	Allogeneic	T-Cells	Autoimmune Disease
Imugene	Azer-cel	1/2	Allogeneic	T-Cells	Hematological Malignancies
Kamau Therapeutics	Nula-Cel	1/2	Autologous	HSCs	Sickle Cell Disease
KSQ Therapeutics	KSQ-001EX	1/2	Autologous	TILs	Advanced Solid Tumors
KSQ Therapeutics	KSQ-004EX	1/2	Autologous	TILs	Advanced Solid Tumors
TG Therapeutics	Azer-cel	1	Allogeneic	T-Cells	Multiple Sclerosis
Vittoria Biotherapeutics	VIPER-101	1	Autologous	T-Cells	T-Cell Lymphoma
Undisclosed Partner B	-	1	Undisclosed	Undisclosed	Undisclosed
Undisclosed Partner C	-	1	Undisclosed	Undisclosed	Undisclosed


As of March 2026/ Includes with SPL Programs with multiple Clinical Trials for different indications

Expanding Opportunity: Growth in Therapeutic Areas and Clinical SPL Programs


SPL Trials Across Multiple Therapeutic Areas

Therapeutic Area	Clinical/Commercial	Pre-Clinical
Genetic Disease	6	1
Blood Cancer	4	0
Solid Tumor	2	15
Autoimmune Disease	2	0
Neurodegenerative Disease	0	2
Total	14	18

SPL Programs (Clinical & Commercial)






MaxCyte Supports the Future of Cell & Gene Therapies



MaxCyte's supports a diverse portfolio of product candidates with significant development milestone and commercial royalty potential

Source: Evaluate Pharma, Broker Estimates and MaxCyte Internal Estimates as of March 2026

Second Wave Set to Enter Pivotal Studies in Next 6 to 18 Months

SPL	Clinical Programs	Phase	Cell Type	Cell Approach	Indication
	CTX112	1/2	T-cells	Allogeneic	B-cell Malignancies
	WU-CART-007	Pivotal	T-cells	Allogeneic	Hematologic Malignancies
	Azer-Cel	1/1b	T-Cells	Allogeneic	Hematologic Malignancies
<i>Undisclosed</i>	<i>Undisclosed Program</i>	1	<i>Undisclosed</i>	<i>Undisclosed</i>	<i>Undisclosed</i>
<i>Undisclosed</i>	<i>Undisclosed Program</i>	Pivotal	<i>Undisclosed</i>	<i>Undisclosed</i>	<i>Undisclosed</i>


Illustrative Revenue Profile for a Successful SPL Program

Revenue Growth Drivers: Significant development milestones and high-value participation in future commercial success of partners' programs

Assumptions: First Approval in Year 7 | Approval in Three Geographic Regions
 \$1.0B Peak Sales | Peak Sales Commercial Year 7 | Royalty 1.0%

- GTx Annual License Fee: \$0.25M/yr. (per GTx)
- Development/Regulatory Milestone: ~\$12M
- Royalty Payments in Aggregate: ~\$79M

+ Increasing PA Sales Through Clinical Development and Commercialization



Thank you! Any questions?

ir@maxcyte.com



©2025 MaxCyte, Inc. All rights reserved. For a complete list of MaxCyte trademarks in the United States and other countries, please visit maxcyte.com/trademarks.

All other trademarks are the property of their respective owners.